Manas AI builds neuro-symbolic, science-based foundational models that analyze biological data to discover and develop transformative medicines. Co-founded by Dr. Siddhartha Mukherjee, Reid Hoffman, and Ujjwal Singh, the company positions itself as an AI-native drug developer rather than a traditional biotech. Its core product suite consists of proprietary large-scale models designed to accelerate target identification, molecule generation, and pre-clinical validation. The newly raised capital will be directed toward further refining these models and advancing ongoing therapeutic campaigns. Since launch, the startup has secured a total of $50.6 million across two seed financings ($24.6 million in January 2025 and a $26 million extension in September 2025). Investors span top technology and life-science funds, signaling cross-sector confidence in Manas AI’s hybrid AI-biotech approach.

Total raised

$51M

Funding rounds

2

Latest round

Seed

Latest activity

Sep 2025